472 related articles for article (PubMed ID: 18990507)
1. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
[TBL] [Abstract][Full Text] [Related]
2. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
5. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients.
Palma DA; van Sörnsen de Koste J; Verbakel WF; Vincent A; Senan S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):974-8. PubMed ID: 20932655
[TBL] [Abstract][Full Text] [Related]
6. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Koshy M; Malik R; Weichselbaum RR; Sher DJ
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
8. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
[TBL] [Abstract][Full Text] [Related]
9. [An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].
Guillerme F; Clavier JB; Schumacher C; Falcoz PE; Bourrhala K; Santelmo N; Hassler S; Schott R; Quoix E; Massard G; Noël G
Cancer Radiother; 2013; 17(4):272-81. PubMed ID: 23712043
[TBL] [Abstract][Full Text] [Related]
10. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
[TBL] [Abstract][Full Text] [Related]
11. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
[TBL] [Abstract][Full Text] [Related]
12. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation.
Guckenberger M; Wulf J; Mueller G; Krieger T; Baier K; Gabor M; Richter A; Wilbert J; Flentje M
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):47-54. PubMed ID: 18977095
[TBL] [Abstract][Full Text] [Related]
13. Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm.
Latifi K; Oliver J; Baker R; Dilling TJ; Stevens CW; Kim J; Yue B; Demarco M; Zhang GG; Moros EG; Feygelman V
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1108-13. PubMed ID: 24529716
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
Parks J; Kloecker G; Woo S; Dunlap NE
Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
17. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
Zimmermann FB; Geinitz H; Schill S; Thamm R; Nieder C; Schratzenstaller U; Molls M
Acta Oncol; 2006; 45(7):796-801. PubMed ID: 16982542
[TBL] [Abstract][Full Text] [Related]
19. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors.
Trakul N; Chang CN; Harris J; Chapman C; Rao A; Shen J; Quinlan-Davidson S; Filion EJ; Wakelee HA; Colevas AD; Whyte RI; Dieterich S; Maxim PG; Hristov D; Tran P; Le QT; Loo BW; Diehn M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):231-7. PubMed ID: 22381907
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
